$5.16
2.64% yesterday
NYSE, Aug 01, 10:00 pm CET
ISIN
US05380C1027
Symbol
RCEL

AVITA Therapeutics Stock price

$5.16
-0.11 2.09% 1M
-3.71 41.83% 6M
-7.64 59.69% YTD
-3.57 40.86% 1Y
-0.76 12.84% 3Y
-17.34 77.07% 5Y
-1.09 17.44% 10Y
-19.84 79.36% 20Y
NYSE, Closing price Fri, Aug 01 2025
-0.14 2.64%
ISIN
US05380C1027
Symbol
RCEL
Industry

Key metrics

Basic
Market capitalization
$136.4m
Enterprise Value
$152.1m
Net debt
$15.7m
Cash
$25.8m
Shares outstanding
26.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.9 | 1.4
EV/Sales
2.1 | 1.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.6%
Return on Equity
-1,374.3%
ROCE
-108.5%
ROIC
-173.7%
Debt/Equity
-9.1
Financials (TTM | estimate)
Revenue
$71.7m | $101.0m
EBITDA
$-49.1m | $-23.4m
EBIT
$-50.6m | $-22.6m
Net Income
$-57.1m | $-18.4m
Free Cash Flow
$-46.6m
Growth (TTM | estimate)
Revenue
41.3% | 57.2%
EBITDA
-0.2% | 57.3%
EBIT
-1.7% | 59.7%
Net Income
-27.3% | 70.2%
Free Cash Flow
10.4%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
-68.6% | -23.2%
EBIT
-70.6%
Net
-79.6% | -18.3%
Free Cash Flow
-65.1%
More
EPS
$-2.2
FCF per Share
$-1.8
Short interest
21.8%
Employees
260
Rev per Employee
$250.0k
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

10x Buy
77%
2x Hold
15%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

Buy
77%
Hold
15%
Sell
8%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
72 72
41% 41%
100%
- Direct Costs 9.70 9.70
31% 31%
14%
62 62
43% 43%
86%
- Selling and Administrative Expenses 91 91
26% 26%
127%
- Research and Development Expense 21 21
0% 0%
30%
-49 -49
0% 0%
-69%
- Depreciation and Amortization 1.44 1.44
106% 106%
2%
EBIT (Operating Income) EBIT -51 -51
2% 2%
-71%
Net Profit -57 -57
27% 27%
-80%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
5 days ago
VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025.
Neutral
GlobeNewsWire
about 2 months ago
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards.
Neutral
Seeking Alpha
3 months ago
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to ...
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today